Business

Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings… Read more . . .

Inhaled drug developer Pulmatrix announced that it has licensed a portfolio of kinase inhibitors from Janssen Biotech subsidiary RespiVert that it plans to develop as inhaled therapies for respiratory diseases. According to a form filed… Read more . . .

Windtree Therapeutics has signed an agreement with Hong-Kong based Lee’s Pharmaceutical Limited for the development and commercialization of Aerosurf and other KL4 surfactant products in a number of Asian countries, the company said. Lee’s will… Read more . . .

The Grünenthal Group will acquire rights to all dosage forms of Zomig zolmitriptan for the treatment of migraines and cluster headaches, including Zomig nasal spray, from AstraZeneca for $200 million up front plus up to… Read more . . .

Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet’s Sprix ketorolac tromethamine nasal spray to women’s healthcare practitioners in the US in the third quarter of 2017 and will continue for at least… Read more . . .

US grocer Albertsons will begin selling Lupin’s InspiraChamber antistatic valved holding chamber exclusively in more than 1,700 pharmacies in 35 US states, Lupin has announced. The InspiraChamber spacer can be used with one of several… Read more . . .

Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments,… Read more . . .

Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .

Pharmaxis has announced that Chiesi Farmaceutici will take over marketing and distribution of Bronchitol mannitol DPI in Italy. Bronchitol has been approved in the EU for the treatment of cystic fibrosis in patients 18 years… Read more . . .